Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 4/20 | 0.31 |
| ▸ | CA12 | O43570 | 3/20 | 0.31 |
| ▸ | CA1 | P00915 | 3/20 | 0.31 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | CA9 | Q16790 | 3/20 | 0.31 |
| ▸ | MMP1 | P03956 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11301792 | 0.93 | — | — | |
| SCHEMBL10397273 | 0.77 | MMP2 (0.34) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL7737909 | 0.77 | SMN1; SMN2 (0.40) | GAASMN1; SMN2 | |
| SCHEMBL10397021 | 0.72 | MMP2 (0.34) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL28440452 | 0.72 | ANPEP (0.34) | ANPEP | |
| SCHEMBL10396838 | 0.71 | — | — | |
| SCHEMBL28675807 | 0.67 | ANPEP (0.34) | ANPEP | |
| SCHEMBL25642458 | 0.67 | INPP5A (0.38) | MEN1KMT2A | |
| SCHEMBL26919943 | 0.67 | INPP5A (0.38) | MEN1KMT2A | |
| SCHEMBL10339393 | 0.66 | ENO1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557783-B2 | Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders | Pharmaxis Pty Limited (AU) | 2013-10-15 | — | — | US | claimed |
| EP-2424542-A1 | PHOSPHOTETRAHYDROPYRAN COMPOUNDS FOR THE TREATMENT OF WOUNDS AND FIBROTIC DISORDERS | Pharmaxis Pty Ltd. (AU) | 2012-03-07 | — | — | EP | claimed |
| US-20120045455-A1 | PHOSPHOTETRAHYDROPYRAN COMPOUNDS FOR THE TREATMENT OF WOUNDS AND FIBROTIC DISORDERS | Pharmaxis Pty Limited (AU) | 2012-02-23 | — | — | US | claimed |
| WO-2010125445-A1 | PHOSPHOTETRAHYDROPYRAN COMPOUNDS FOR THE TREATMENT OF WOUNDS AND FIBROTIC DISORDERS | PHARMAXIS PTY LTD. (AU) | 2010-11-04 | — | — | WO | claimed |
| CN-108191909-B | Process for preparing glufosinate-ammonium acid by hydrogenation method | ATI化学国际公司 | 2020-05-01 | — | — | CN | disclosed |
| US-8557783-B2 | Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders | Pharmaxis Pty Limited (AU) | 2013-10-15 | — | — | US | disclosed |
| US-8557783-B2 | Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders | Pharmaxis Pty Limited (AU) | 2013-10-15 | — | — | US | disclosed |
| US-8557783-B2 | Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders | Pharmaxis Pty Limited (AU) | 2013-10-15 | — | — | US | disclosed |
| EP-2424542-A1 | PHOSPHOTETRAHYDROPYRAN COMPOUNDS FOR THE TREATMENT OF WOUNDS AND FIBROTIC DISORDERS | Pharmaxis Pty Ltd. (AU) | 2012-03-07 | — | — | EP | disclosed |
| EP-2424542-A1 | PHOSPHOTETRAHYDROPYRAN COMPOUNDS FOR THE TREATMENT OF WOUNDS AND FIBROTIC DISORDERS | Pharmaxis Pty Ltd. (AU) | 2012-03-07 | — | — | EP | disclosed |
| US-20120045455-A1 | PHOSPHOTETRAHYDROPYRAN COMPOUNDS FOR THE TREATMENT OF WOUNDS AND FIBROTIC DISORDERS | Pharmaxis Pty Limited (AU) | 2012-02-23 | — | — | US | disclosed |
| US-20120045455-A1 | PHOSPHOTETRAHYDROPYRAN COMPOUNDS FOR THE TREATMENT OF WOUNDS AND FIBROTIC DISORDERS | Pharmaxis Pty Limited (AU) | 2012-02-23 | — | — | US | disclosed |
| EP-1301522-A4 | NOVEL COMPOUNDS AND METHODS | PHARMAXIS PTY LTD (AU) | 2004-04-14 | — | — | EP | disclosed |
| US-20030176363-A1 | Novel compounds and methods | PHARMAXIS PTY LTD. (AU) | 2003-09-18 | — | — | US | disclosed |
| US-20030176363-A1 | Novel compounds and methods | PHARMAXIS PTY LTD. (AU) | 2003-09-18 | — | — | US | disclosed |
| EP-1301522-A1 | NOVEL COMPOUNDS AND METHODS | Pharmaxis Pty Ltd (AU) | 2003-04-16 | — | — | EP | disclosed |
| EP-1301522-A1 | NOVEL COMPOUNDS AND METHODS | Pharmaxis Pty Ltd (AU) | 2003-04-16 | — | — | EP | disclosed |
| US-6415234-B1 | USING COMPUTERS | GLYCO DESIGN INC. | 2002-07-02 | — | — | US | disclosed |
| WO-2002004472-A1 | NOVEL COMPOUNDS AND METHODS | PHARMAXIS PTY LTD (AU) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004472-A1 | NOVEL COMPOUNDS AND METHODS | PHARMAXIS PTY LTD (AU) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176363-A1 | Novel compounds and methods | NFATC1, CD4, CCR5 | GAA 3092/4885SMN1; SMN2 3351/4885ANPEP 1824/4885 |
| US-20120045455-A1 | PHOSPHOTETRAHYDROPYRAN COMPOUNDS FOR THE TREATMENT OF WOUNDS AND FIBROTIC DISORDERS | PTGIS, PTGIR, AGT | GAA 3235/4885SMN1; SMN2 4782/4885ANPEP 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.